Pattraporn Satitsuksanoa1, Anna Głobińska1,2, Kirstin Jansen1, Willem van de Veen1, Mübeccel Akdis3. 1. Swiss Institute of Allergy and Asthma Research (SIAF), Obere Strasse 22, CH-7270, Davos, Switzerland. 2. Immunology, Rheumatology and Allergy Department, Medical University of Lodz, Lodz, Poland. 3. Swiss Institute of Allergy and Asthma Research (SIAF), Obere Strasse 22, CH-7270, Davos, Switzerland. akdism@siaf.uzh.ch.
Abstract
PURPOSE OF REVIEW: During the past few decades, modified allergens have been developed for use in allergen-specific immunotherapy (AIT) with the aim to improve efficacy and reduce adverse effects. This review aims to provide an overview of the different types of modified allergens, their mechanism of action and their potential for improving AIT. RECENT FINDINGS: In-depth research in the field of allergen modifications as well as the advance of recombinant DNA technology have paved the way for improved diagnosis and research on human allergic diseases. A wide range of structurally modified allergens has been generated including allergen peptides, chemically altered allergoids, adjuvant-coupled allergens, and nanoparticle-based allergy vaccines. These modified allergens show promise for the development of AIT regimens with improved safety and long-term efficacy. Certain modifications ensure reduced IgE reactivity and retained T cell reactivity, which facilities induction of immune tolerance to the allergen. To date, multiple clinical trials have been performed using modified allergens. Promising results were obtained for the modified cat, grass and birch pollen, and house dust mite allergens. The use of modified allergens holds promise for improving AIT efficacy and safety. There is however a need for larger clinical studies to reliably assess the added benefit for the patient of using modified allergens for AIT.
PURPOSE OF REVIEW: During the past few decades, modified allergens have been developed for use in allergen-specific immunotherapy (AIT) with the aim to improve efficacy and reduce adverse effects. This review aims to provide an overview of the different types of modified allergens, their mechanism of action and their potential for improving AIT. RECENT FINDINGS: In-depth research in the field of allergen modifications as well as the advance of recombinant DNA technology have paved the way for improved diagnosis and research on humanallergic diseases. A wide range of structurally modified allergens has been generated including allergen peptides, chemically altered allergoids, adjuvant-coupled allergens, and nanoparticle-based allergy vaccines. These modified allergens show promise for the development of AIT regimens with improved safety and long-term efficacy. Certain modifications ensure reduced IgE reactivity and retained T cell reactivity, which facilities induction of immune tolerance to the allergen. To date, multiple clinical trials have been performed using modified allergens. Promising results were obtained for the modified cat, grass and birch pollen, and house dust mite allergens. The use of modified allergens holds promise for improving AIT efficacy and safety. There is however a need for larger clinical studies to reliably assess the added benefit for the patient of using modified allergens for AIT.
Authors: Antonio Basomba; Ana I Tabar; Dolores Hernández F de Rojas; Blanca E García; Remedios Alamar; José M Olaguíbel; Jaime Moscoso del Prado; Santiago Martín; Pilar Rico Journal: J Allergy Clin Immunol Date: 2002-06 Impact factor: 10.793
Authors: Gabrielle Pauli; Tina H Larsen; Sabina Rak; Friedrich Horak; Elide Pastorello; Rudolf Valenta; Rudolph Valenta; Ashok Purohit; Monica Arvidsson; Alexander Kavina; Jan W Schroeder; Nadine Mothes; Susanne Spitzauer; Armelle Montagut; Sylvie Galvain; Michel Melac; Claude André; Lars K Poulsen; Hans-Jorgen Malling Journal: J Allergy Clin Immunol Date: 2008-11 Impact factor: 10.793
Authors: A Roger Reig; M Ibero Iborra; T Carrillo Díaz; R López Abad; V Sánchez Moreno; J Álvarez Nieto; N Cancelliere Journal: Eur Ann Allergy Clin Immunol Date: 2017-05
Authors: Philippe Bégin; Tina Dominguez; Shruti P Wilson; Liane Bacal; Anjuli Mehrotra; Bethany Kausch; Anthony Trela; Morvarid Tavassoli; Elisabeth Hoyte; Gerri O'Riordan; Alanna Blakemore; Scott Seki; Robert G Hamilton; Kari C Nadeau Journal: Allergy Asthma Clin Immunol Date: 2014-02-20 Impact factor: 3.406